Weight-loss and diabetes drugs now generate most of Eli Lilly (LLY)'s sales, and revenue rose 38.6% in the third quarter from a year earlier. Revenue was $24.40B in the quarter ended Sept. 30, 2026, above the analyst estimate of $22.58B. The shares traded at 1443.5 USD on the latest quote (Nov. 13, 2026), 1.1% below the 52-week high of 1460 USD.
The idea
The theme is a drugmaker leaning on one drug family. Cardiometabolic drugs treat conditions tied to weight, blood sugar and the heart. When one family becomes the bulk of sales, growth can be fast, but the company's results depend on that one area.
For an investor, the questions are how big that area is, whether profit keeps pace with sales, and what the price already assumes.
The example
In the quarter ended Sept. 30, 2026, Cardiometabolic Health revenue was $19.76B. Oncology was $2.60B, Immunology $1.44B and Neuroscience $444.0M. Cardiometabolic is therefore the large majority of the $24.40B total.
Adjusted earnings per share were 7.48 against an analyst estimate of 5.71, a difference of +$1.77, or 31.0%. Diluted EPS under standard accounting was 7.22, against 6.21 a year earlier. Net income was $6.45B, up 15.6% from a year earlier.
Profit grew more slowly than sales. Operating margin, the share of revenue left after running the business, was 35.3% in the quarter. In the prior quarter ended June 30, 2026, it was 54.2%. The data we have does not say why, and we do not offer a reason.
Cash generation was strong. Free cash flow, the cash left after capital spending, was $8.22B in the quarter. Operating cash flow was $11.40B and capital expenditure was $3.18B.
Sales are also concentrated at home. United States revenue was $15.14B, Europe $4.46B and China $947.0M.
A Zacks report on Nov. 13, 2026 said telehealth company Hims & Hers (HIMS) has partnered with Lilly to offer FDA-approved weight-loss drugs. It is another sign of the category reaching more patients.
Our MoonshotScore for Lilly is 98, with growth the strongest section and valuation the weakest.
Risks
- Price already high. The trailing price-to-earnings ratio, which compares the share price with profit per share, is 46.73. AbbVie (ABBV) has a P/E of 50.61 and Johnson & Johnson (JNJ) has a P/E of 43.32, while Amgen (AMGN) has 26.79 and AstraZeneca (AZN) has 25.95.
- Debt. Total debt was $49.50B against cash and short-term investments of $4.88B at Sept. 30, 2026. FMP reports net debt of $44.62B.
- Margin swing. Operating margin was lower than in the prior quarter. If it stays low, profit may trail sales.
What to watch next
- Feb. 3, 2027: the next earnings report, 82 days after the Nov. 13, 2026 quote. Analysts estimate EPS of 11.19 and revenue of $24.58B.
- Operating margin: whether it recovers from 35.3%.
- Cash returns: buybacks were $377.0M in the third quarter, against $1.60B in the second.
- Insider activity: the latest filings show 0 open-market purchases and 1 sale in the last 90 days.
Key facts
- Oct. 29, 2026: Lilly reported adjusted EPS of 7.48 against an estimate of 5.71, and revenue of $24.40B against an estimate of $22.58B.
- Q3 ended Sept. 30, 2026: net income was $6.45B and operating income was $8.61B.
- Nov. 13, 2026: the share price was 1443.5 USD, up 1.26% on the latest quote, and 69.7% above the 52-week low of 850.51 USD.
- Analyst targets: the consensus average target is 1442.44 USD, with a range of 940.00 USD to 1650.00 USD, from 46 ratings with a consensus of Buy.
- Valuation model: FMP's discounted cash flow model estimates 818.49 USD per share as of Nov. 14, 2026.
| Metric | Q3 FY2026 | Q3 FY2025 |
|---|---|---|
| Revenue | $24.40B | $17.60B |
| Operating income | $8.61B | $8.39B |
| Net income | $6.45B | $5.58B |
| Diluted EPS | 7.22 | 6.21 |
Frequently asked questions
Q: How much of Eli Lilly's revenue comes from obesity and diabetes drugs?
In the quarter ended Sept. 30, 2026, Cardiometabolic Health revenue was $19.76B out of $24.40B in total revenue, the large majority of sales.Q: Did Eli Lilly beat estimates in the third quarter?
Yes. Adjusted EPS was 7.48 against an analyst estimate of 5.71, and revenue was $24.40B against an estimate of $22.58B, according to FMP data for the report of Oct. 29, 2026.Q: When does Eli Lilly report next?
The next earnings date is Feb. 3, 2027. Analysts estimate EPS of 11.19 and revenue of $24.58B for that report.This is educational content, not investment advice. Past performance does not guarantee future results.
